Striatal and extrastriatal microPET imaging of D2/D3 dopamine receptors in rat brain with [18F]fallypride and [18F]desmethoxyfallypride

In this study, we compared two different D2/3 receptor ligands, [18F]fallypride and [18F]desmethoxyfallypride ([18F]DMFP) with respect to the duration of the scan, visualization of extrastriatal receptors, and binding potentials (BPND) in the rat brain. In addition, we studied the feasibility of using these tracers following a period of awake tracer uptake, during which the animal may perform a behavioral task. Male Sprague–Dawley rats were imaged with [18F]fallypride and with [18F]DMFP in four different studies using microPET. All scans were performed under isoflurane anesthesia. The first (test) and second (retest) study were 150‐min baseline scans. No retest scans were performed with [18F]DMFP. A third study was a 60‐min awake uptake of radiotracer followed by a 90‐min scan. A fourth study was a 150‐min competition scan with haloperidol (0.2 mg/kg) administered via tail vein at 90‐min post‐[18F]fallypride injection and 60‐min post‐[18F]DMFP. For the test–retest studies, BPND was measured using both Logan noninvasive (LNI) method and the interval ratios (ITR) method. Cerebellum was used as a reference region. For the third study, the binding was measured only with the ITR method, and the results were compared to the baseline results. Studies showed that the average transient equilibrium time in the dorsal striatum (DSTR) was at 90 min for [18F]fallypride and 30 min for [18F]DMFP. The average BPND for [18F]fallypride was 14.4 in DSTR, 6.8 in ventral striatum (VSTR), 1.3 in substantia nigra/ventral tegmental area (SN/VTA), 1.4 in colliculi (COL), and 1.5 in central gray area. In the case of [18F]DMFP, the average BPND values were 2.2 in DSTR, 2.7 in VSTR, and 0.8 in SN/VTA. The haloperidol blockade showed detectable decrease in binding of both tracers in striatal regions with a faster displacement of [18F]DMFP. No significant changes in BPND of [18F]fallypride due to the initial awake state of the animal were found, whereas BPND of [18F]DMFP was significantly higher in the awake state compared to baseline. We were able to demonstrate that dynamic PET using MicroPET Inveon allows quantification of both striatal and extrastriatal [18F]fallypride binding in rats in vivo. Quantification of the striatal regions could be achieved with [18F]DMFP. Synapse 2011. © 2011 Wiley‐Liss, Inc.

[1]  Dianne E. Lee,et al.  Imaging dopamine release with Positron Emission Tomography (PET) and 11C-raclopride in freely moving animals , 2008, NeuroImage.

[2]  Peter Herscovitch,et al.  Comparison of Bolus and Infusion Methods for Receptor Quantitation: Application to [18F]Cyclofoxy and Positron Emission Tomography , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[3]  Jogeshwar Mukherjee,et al.  Measuring the in Vivo Binding Parameters of [18F]-Fallypride in Monkeys Using a PET Multiple-Injection Protocol , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[4]  Jogeshwar Mukherjee,et al.  Performance evaluation of an Inveon PET preclinical scanner , 2008, Physics in medicine and biology.

[5]  Judy Illes,et al.  Brain Imaging , 2006, Science communication.

[6]  Bradley T. Christian,et al.  Measurement of d-amphetamine-induced effects on the binding of dopamine D-2/D-3 receptor radioligand, 18F-fallypride in extrastriatal brain regions in non-human primates using PET , 2005, Brain Research.

[7]  Mark Slifstein,et al.  Revisiting an Old Issue: The Discrepancy Between Tissue Ratio–Derived Binding Parameters and Kinetic Modeling–Derived Parameters After a Bolus of the Serotonin Transporter Radioligand 123I-ADAM , 2008, Journal of Nuclear Medicine.

[8]  G Blomqvist,et al.  Comparison of the Transient Equilibrium and Continuous Infusion Method for Quantitative PET Analysis of [11C]Raclopride Binding , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  L. Swanson The Rat Brain in Stereotaxic Coordinates, George Paxinos, Charles Watson (Eds.). Academic Press, San Diego, CA (1982), vii + 153, $35.00, ISBN: 0 125 47620 5 , 1984 .

[10]  N. Volkow,et al.  Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[11]  Mark Slifstein,et al.  Effect of amphetamine on [18F]fallypride in vivo binding to D2 receptors in striatal and extrastriatal regions of the primate brain: Single bolus and bolus plus constant infusion studies , 2004, Synapse.

[12]  D. Todman Synapse , 2009, European Neurology.

[13]  Markus Piel,et al.  Quantification of D 2-Like Dopamine Receptors in the Human Brain with 18 F-Desmethoxyfallypride , 2002 .

[14]  P D Leeson,et al.  3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor. , 1996, Journal of medicinal chemistry.

[15]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[16]  Qinan Bao,et al.  Performance Evaluation of the Inveon Dedicated PET Preclinical Tomograph Based on the NEMA NU-4 Standards , 2009, Journal of Nuclear Medicine.

[17]  Paul Cumming,et al.  Parametric mapping of binding in human brain of D2 receptor ligands of different affinities. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  P Jeffrey Conn,et al.  [(18)F]Fallypride dopamine D2 receptor studies using delayed microPET scans and a modified Logan plot. , 2009, Nuclear medicine and biology.

[19]  B. Christian,et al.  Brain imaging of 18F‐fallypride in normal volunteers: Blood analysis, distribution, test‐retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D‐2/D‐3 receptors , 2002, Synapse.

[20]  Paul Cumming,et al.  Endogenous competition against binding of [18F]DMFP and [18F]fallypride to dopamine D2/3 receptors in brain of living mouse , 2010, Synapse.

[21]  M. K. Das,et al.  Fluorinated benzamide neuroleptics--III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. , 1995, Nuclear medicine and biology.

[22]  Mark Slifstein,et al.  In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates , 2004, Psychopharmacology.

[23]  Markus Piel,et al.  Quantification of D2-like dopamine receptors in the human brain with 18F-desmethoxyfallypride. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  Bruno Giros,et al.  Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA , 1991, Brain Research.

[25]  Richard J. Davidson,et al.  The Distribution of D2/d3 Receptor Binding in the Adolescent Rhesus Monkey Using Small Animal Pet Imaging , 2022 .

[26]  Javier Pavía,et al.  Test–retest variability and reliability of 123I‐IBZM SPECT measurement of striatal dopamine D2 receptor availability in healthy volunteers and influence of iterative reconstruction algorithms , 2008, Synapse.

[27]  Allan C. Branch Parametric mapping , 1997, Mobile Robots.

[28]  B. Christian,et al.  Quantitation of striatal and extrastriatal D‐2 dopamine receptors using PET imaging of [18F]fallypride in nonhuman primates , 2000, Synapse.

[29]  J. Mukherjee,et al.  18F-desmethoxyfallypride: a fluorine-18 labeled radiotracer with properties similar to carbon-11 raclopride for PET imaging studies of dopamine D2 receptors. , 1996, Life sciences.

[30]  N. Vandehey PET ASSAY OF EXTRASTRIATAL DOPAMINE D 2 /D 3 RECEPTORS , 2009 .

[31]  Jesper L. R. Andersson,et al.  A template for spatial normalisation of MR images of the rat brain , 2003, Journal of Neuroscience Methods.